文献速递类风湿关节炎

无DMARD缓解作为类风湿关节炎新治疗目标:可行性与可持续性的系统文献综述

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.
PubMed 文献 · RMD Open · 2020-01-01

该系统综述纳入51项研究(14项临床试验和5项观察性研究),评估类风湿关节炎患者实现无DMARD缓解(DFR)的可行性与可持续性。高质量和中质量研究中DFR实现率为5.0%-24.3%,持续DFR(>12个月)为11.6%-19.4%;DMARD减量期间复发频繁(41.8%-75.0%),DFR后第一年复发率为10.4%-11.8%,晚期复发少见(0.3%-3.5%)。自身抗体和共享表位等位基因缺失与DFR实现概率增加相关。

要点

  • DFR在RA中可实现,约10%-20%患者可持续,但定义需统一。
  • DMARD减量期复发率高(41.8%-75.0%),DFR后第一年复发率10.4%-11.8%。
  • 自身抗体和共享表位等位基因缺失与DFR实现概率增加相关。

核心结论

  • DFR在RA中可实现,约10%-20%患者可持续。
  • DFR可作为临床试验重要结局指标,但需统一定义。
  • 鉴于停药后第一年复发率高,建议DFR后随访>12个月以评估可持续性。

研究设计与样本

  • 系统文献检索于2019年3月在多个数据库进行,纳入报告RA缓解患者停用DMARD的临床试验和观察性研究。
  • 共纳入51篇文章,包括14项临床试验和5项观察性研究;质量评估包括总体评估和DFR描述评估。

主要发现

  • 仅考虑高质量和中质量研究,DFR实现率为5.0%-24.3%,持续DFR(>12个月)为11.6%-19.4%(均相对于符合减量条件的患者数)。
  • DMARD减量期间复发率为41.8%-75.0%,达到DFR后第一年复发率为10.4%-11.8%,停药>1年的晚期复发率为0.3%-3.5%。
  • 许多患者特征与DFR无关联;自身抗体和共享表位等位基因缺失增加DFR实现机会。

关键数值与推荐

  • DFR定义存在差异,尤其关于无DMARD状态的持续时间。
  • 高质量和中质量研究中DFR实现率为5.0%-24.3%,持续DFR(>12个月)为11.6%-19.4%。
  • DMARD减量期间复发率为41.8%-75.0%,DFR后第一年复发率为10.4%-11.8%,晚期复发率为0.3%-3.5%。

临床怎么用

  • 对于RA缓解患者,可考虑DMARD减量,但需监测减量期间的高复发风险。
  • 达到DFR后应至少随访12个月以评估可持续性,因第一年复发率较高。
  • 自身抗体和共享表位等位基因缺失可能提示更高的DFR实现概率,可辅助临床决策。

局限性

  • DFR定义不一致,尤其无DMARD持续时间,影响结果可比性。
  • 仅纳入2019年3月前发表文献,可能遗漏后续研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although current treatment guidelines for rheumatoid arthritis (RA) suggest tapering disease-modifying anti-rheumatic drugs (DMARDs), it is unclear whether DMARD-free remission (DFR) is an achievable and sustainable outcome. Therefore, we systematically reviewed the literature to determine the prevalence and sustainability of DFR and evaluated potential predictors for DFR. METHODS: A systematic literature search was performed in March 2019 in multiple databases. All clinical trials and observational studies reporting on discontinuation of DMARDs in RA patients in remission were included. Our quality assessment included a general assessment and assessment of the description of DFR. Prevalence of DFR and its sustainability and flares during tapering and after DMARD stop were summarised. Also, potential predictors for achieving DFR were reviewed. RESULTS: From 631 articles, 51 were included, comprising 14 clinical trials and 5 observational studies. DFR definition differed, especially for the duration of DMARD-free state. Considering only high- and moderate-quality studies, DFR was achieved in 5.0%-24.3% and sustained DFR (duration>12 months) in 11.6%-19.4% (both relative to the number of patients eligible for tapering). Flares occurred frequently during DMARD tapering (41.8%-75.0%) and in the first year after achieving DFR (10.4%-11.8%), while late flares, >1 year after DMARD-stop, were infrequent (0.3%-3.5%). Many patient characteristics lacked association with DFR. Absence of autoantibodies and shared epitope alleles increased the chance of achieving DFR. CONCLUSIONS: DFR is achievable in RA and is sustainable in ~10%-20% of patients. DFR can become an important outcome measure for clinical trials and requires consistency in the definition. Considering the high rate of flares in the first year after DMARD stop, a DMARD-free follow-up of >12 months is advisable to evaluate sustainability.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Verstappen M, van Mulligen E, de Jong PHP, et al. DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability. RMD Open. 2020. PMID: 32393523. doi:10.1136/rmdopen-2020-001220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。